Nemocnice Pardubickeho kraje a.s. — Clinical Trial Site

50 Registered trials

13 Currently recruiting

Organisation

Nemocnice Pardubickeho kraje a.s.

Location

Pardubice, Czechia

Identifier

ORG-100044771

Address

Kyjevska 44, 532 03, Czechia

Departments

#2052: Neurologicka klinika, MS Centrum
#2100; Interni klinika-Kardiologicke oddelelni
#3154:Kardiologie
#3159:Interní klinika-Kardiologické odd
#7203: Neurologické oddělení
2316: Interní klinika-Kardiologické odd
3159: Interni klinika-Kardiologicke odd.
7503: Interni oddeleni
7525: Kardiologicke oddeleni
Cardiology
Dermatology
Internal
Internal Clinic, Department of Cardiology
Interni klinika - Kardiologicke oddeleni
Interni oddeleni
Kardiologické oddělení
Kardiologie
Klinika otorinolaryngologie a chirurgie hlavy a krku
Klinika otorinolaryngologie a chirurgie hlavy a krku
n/a
Nemocnice Pardubickeho kraje Pardubicka nemocnice
Neurologicka klinika
Neurologická klinika /Clinic of Neurology
Neurologická klinika, MS Centrum
Neurologické oddělení
Neurologie
Neurologie - RS centrum
Neurologie/MS centrum
Neurology
Oční oddělení
Oddělení interní medicíny
Orthopaedic clinic
Paediatrics and newborn department
Radiodiagnostické oddělení
Usni, Nosni, Krcni

Clinical trials at this site (50)

Search interface

ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok… Ended

2023-505810-12-00 Lower limb spasticity 5 2019-09-03
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Ulcerative Colitis 5 2017-01-02
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Ended

2022-502481-24-00 Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) 4 2024-05-23
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe… Ended

2022-501884-41-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-29
A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno… Ended

2022-501885-24-00 Contrast enhancement in magnetic resonance imaging for 5 2023-09-20
A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended

2022-502174-16-00 Macular edema secondary to retinal vein occlusion 5 2023-09-13
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Ended

2024-517612-29-00 acute heart failure 11 2023-02-14
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm… Ended

2024-513658-31-00 Idiopathic Sudden Sensorineural Hearing Loss 4 2022-08-08
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended

2024-514372-40-00 Anterior ST-Elevation Myocardial Infarction 5 2022-04-12
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended

2024-511263-28-00 Hypercholesterolemia 6 2022-04-08
A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous (SC) Ocrelizumab… Ended

2023-505975-54-00 Multiple Sclerosis (MS) 5 2022-03-28
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended

2024-511553-22-00 Moderately to Severely Active Crohn's Disease 5 2018-10-05